Search clinical trials for: Neuroendocrine Tumours

Total 4656 results

Centre Hospitalier Universitaire Dijon

Not yet recruiting

Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation (PRO-NEM1)

Neuroendocrine Tumors | MEN1 Mutation

France
Australasian Gastro-Intestinal Trials Group
Canadian Cancer Trials Group

Not yet recruiting

Cessation of Somatostatin Analogues After PRRT in Mid-Gut Neuroendocrine Tumours (STOPNET)

Neuroendocrine Tumors

Australia
Assistance Publique - Hôpitaux de Paris

Recruiting

Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort (OPERANDI-NET)

Radiotherapy | Gastroenteropancreatic Neuroendocrine Tumor

France
Multitude Therapeutics Inc.

Recruiting

AMT-253 in Patients With Advanced Solid Tumours

Advanced Solid Tumors | Malignant Melanoma

China
IRCCS San Raffaele

Recruiting

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

Gastroenteropancreatic Neuroendocrine Tumor

Italy
IRCCS San Raffaele

Recruiting

Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours (3DPanNET)

Pancreatic Neuroendocrine Tumor

Italy
Boehringer Ingelheim

Recruiting

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Netherlands
Cancer Research UK
Heptares Therapeutics Limited

Recruiting

HTL0039732 in Participants With Advanced Solid Tumours

Sarcoma | Neoplasms | Kidney Neoplasms | Uterine Cervical Neoplasms | Stomach Neoplasms | Head and Neck Neoplasms | Lung Neoplasms | Urinary Bladder Neoplasms | Colorectal Neoplasms | Pancreatic Neoplasms | Esophageal Neoplasms | Mesothelioma, Malignant | Prostatic Neoplasms, Castration-Resistant | Pheochromocytomas

United Kingdom
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Germany, Belgium, Japan, France
EDDC (Experimental Drug Development Centre), A*STAR...
Parexel

Recruiting

A Study of EBC-129 in Advanced Solid Tumours

Advanced Solid Tumours

United States, Singapore
Fusion Pharmaceuticals Inc.

Recruiting

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Gastric Cancer | Colorectal Cancer | Ewing Sarcoma | Squamous Cell Carcinoma of Head and Neck | Pancreatic Ductal Adenocarcinoma (PDAC) | NTSR1 Expressing Solid Tumours | Neuroendocrine Differentiated (NED) Prostate Cancer

United States, Australia
Imperial College London
Advanced Accelerator Applications International SA

Recruiting

Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana)

Neuroendocrine Tumors

United Kingdom
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Peter MacCallum Cancer Centre, Australia

Recruiting

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (PARLuNET)

Neuroendocrine Tumors

Australia
J.M. de Laat
Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaborators

Recruiting

Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients (PRIME)

Multiple Endocrine Neoplasia Type 1 | Neuroendocrine Tumor of Pancreas

Netherlands
King's College London
Guy's and St Thomas' NHS Foundation Trust

Recruiting

Optimising Molecular Radionuclide Therapy (SELFIE)

Hyperthyroidism | Neuroendocrine Tumors | Thyroid Carcinoma | Thyroid Cancer

United Kingdom
Imperial College London

Recruiting

Use of Non-invasive Optical Analysis in Neurosurgery

Glioma | Meningioma | Brain Metastases | Schwannoma | Brain Tumour

United Kingdom
Fundación de investigación HM
Syntax for Science, S.L

Recruiting

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Neuroendocrine Tumours (NET) | Neuroendocrine Carcinomas (NEC)

Spain
University of Roma La Sapienza

Recruiting

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) (REBORN)

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

Italy
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Patients With Small Cell Lung Carcinoma and Other Neoplasms

United States, Spain, Germany, Japan
Imperial College London
Biocompatibles UK Ltd, a BT International group company

Recruiting

TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets (ArTisaN)

Neuroendocrine Tumors | Liver Metastases

United Kingdom
King's College Hospital NHS Trust
Ampersand Health Ltd; Neuroendocrine Cancer UK

Recruiting

Mobile Application to Collect PRO Data in NET Patients

Neuroendocrine Neoplasms (Tumours)

United Kingdom
Uppsala University

Recruiting

Biomarker Study of Pancreatic Neuroendocrine Tumours

Pancreatic Neuroendocrine Tumor

Sweden
AHS Cancer Control Alberta

Recruiting

A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Neuroendocrine Tumors

Canada
AHS Cancer Control Alberta

Recruiting

A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

Carcinoma, Neuroendocrine

Canada
University Hospital Inselspital, Berne
University Hospital, Geneva; University Hospital, Basel, Switzerland; University... and other collaborators

Recruiting

SwissNET - a Registry for Neuroendocrine Tumours in Switzerland (SwissNET)

Neuroendocrine Tumors | Carcinoid Tumor

Switzerland
University Medical Center Groningen

Completed

Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. (BANN)

Carcinoma, Renal Cell | Carcinoma | Neuroendocrine Tumors | Carcinoid Tumor | Pancreatic Islet Cell Tumors

Netherlands
Hutchmed

Active, not recruiting

Open-Label Surufatinib in European Patients With NET

Neuroendocrine Tumours | Neuroendocrine Tumour of the Lung | Small Intestinal NET

Spain, France, United States, United Kingdom, Norway, Germany, Italy
Military Institute od Medicine National Research...

Completed

Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT

Early Release of Chromogranin A (CgA)
Barts & The London NHS Trust

Terminated

CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia

Insulin Resistance | Insulinoma | Hypoglycemia Unawareness | Hypoglycemia Non-Diabetic | Insulin Hypoglycemia | Hypoglycemia, Reactive | Hypoglycaemia Night | Insulinoma; Malignant, Pancreas | Spontaneous Hypoglycemia | Neuro Endocrine Tumours

United Kingdom
Medical University Innsbruck
Novartis

Completed

68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours

Neuroendocrine Tumors

Austria
Vastra Gotaland Region
Advanced Accelerator Applications

Active, not recruiting

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (LuPARP)

Thymoma | Neuroendocrine Tumors | Mesothelioma | Clinical Trial, Phase I

Sweden
Lawson Health Research Institute

Active, not recruiting

An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours

Neuroendocrine Carcinoma

Canada
Olivia Newton-John Cancer Research Institute
Bristol-Myers Squibb

Active, not recruiting

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

Gastrointestinal Cancer | Malignant Female Reproductive System Neoplasm | Neuroendocrine Tumours

Australia
Advanced Accelerator Applications

Active, not recruiting

Post-Authorization Long-Term Safety Study of LUTATHERA (SALUS)

Neuroendocrine Tumors

United Kingdom, Portugal, Spain, France, United States
British Columbia Cancer Agency

No longer available

18F-FDOPA PET in Neuroendocrine Tumours

Thyroid Cancer, Medullary | Neuroblastoma | Pheochromocytoma | Carcinoid Tumor | Paraganglioma | Insulinoma

Canada
Provectus Biopharmaceuticals, Inc.

Active, not recruiting

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Neuroendocrine Tumors Metastatic to the Liver

Australia
Federation Francophone de Cancerologie Digestive

Terminated

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) (REMINET)

Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours

France, Belgium, Germany, United Kingdom
Ipsen

Completed

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)

Midgut Neuroendocrine Tumours | Pancreatic Tumours

Spain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France; European Network for the Study of Adrenal...

Completed

First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (FIRSTMAPPP)

Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)

Italy, France, Germany, Netherlands
Ipsen

Completed

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting (PREF-NET)

Neuroendocrine Tumours (NET)

United Kingdom
Ipsen

Terminated

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (SPINET)

Neuroendocrine Tumors in Lung

Canada, United States, Germany, France, United Kingdom, Netherlands, Spain, Denmark, Italy, Austria, Poland
Australasian Gastro-Intestinal Trials Group

Completed

Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study (CONTROL NETS)

Midgut Neuroendocrine Tumours | Pancreatic Neuroendocrine Tumours

Australia
Centre Hospitalier Universitaire Dijon

Terminated

Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer of the Colon, Stomach, Bile Ducts, Rectum, Pancreas or Lung, or Gastrointestinal Neuroendocrine Tumours (EOLE)

Non-resectable Metastatic Cancer of the Lung | Non-resectable Metastatic Cancer of the Colon | Non-resectable Metastatic Cancer of the Rectosigmoid Junction | Non-resectable Metastatic Cancer of the Stomach | Non-resectable Metastatic Cancer of the Bile Duct | Non-resectable Metastatic Cancer... and other conditions

France
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Ipsen

Terminated

Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (PanNET)

Pancreatic Neuroendocrine Tumor

Spain, Portugal
Grupo Espanol de Tumores Neuroendocrinos
Pfizer

Active, not recruiting

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Neuroendocrine Tumors | Advanced Cancer

Spain, Germany, Italy, United Kingdom
Ipsen

Completed

Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours (QUALINETS)

Gastrointestinal Neuroendocrine Tumours

Spain, Portugal
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Neuroendocrine Tumours

Spain
Ipsen

Withdrawn

Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice (NETways)

Neuroendocrine Tumors

Poland

Search clinical trials for: Neuroendocrine Tumours

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations